Boston-based personal health and predictive analytics company Biofourmis has secured $35 million in Series B funding, according to company database Crunchbase, topping the city’s recent funding headlines. The cash infusion was announced May 21 and led by MassMutual Ventures.
According to its Crunchbase profile, "Biofourmis is a fast-growing global health IT start-up founded in Singapore that augments personalized patient care and therapies with Digital Therapeutics for better management of patients with complex chronic conditions. The company discovers, develops and delivers clinically validated software-based therapeutics to enable better outcomes for patients. These solutions include advanced tools for clinicians to deliver personalized care and cost-effective solutions for payers."
The three-year-old startup has raised six previous funding rounds, including a $2 million Series A round in 2018.
The round brings total funding raised by Boston companies in artificial intelligence over the past month to $46 million. The local artificial intelligence industry has seen 45 funding rounds over the past year, raking in a total of $502 million in venture funding.
In other local funding news, communities company Validity announced a corporate round on May 31.
According to Crunchbase, "Validity was formed to bring confidence to all of us who rely on data every day to run our business. They realize the importance of trusting data and all the challenges their operations encounter once doubt creeps in. As a global industry leader in data quality, their role is to ensure you have the tools you need to tackle the complexities of data administration and regain certainty with the integrity of your data assets."
The company also raised a private equity round in 2018.
This story was created automatically using local investment data, then reviewed by an editor. Click here for more about what we're doing. Got thoughts? Go here to share your feedback.
